Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cong He has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Yin Zhu

    Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China

    13 shared publications
  • Nonghua Lu

    Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University

    7 shared publications
  • Nonghua Lu

    Department of Gastroenterology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330006, P.R. China

    7 shared publications
  • Yu Li

    Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China

    7 shared publications
  • Nianshuang Li

    Jiangxi Provincial Key Laboratory of Digestive Diseases, Department of Gastroenterology, Digestive Disease Hospital The First Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang Jiangxi China

    5 shared publications
  • Xinbo Xu

    Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University

    5 shared publications

Latest Publications

  • A Bidirectional Association Between Helicobacter pylori Infection and Hyperlipidemia: Clinical Evidence and Mechanistic Insights

    by Yan'AN Zhou, Yuchen Zhu, Shuai Li, Zekun He, Yao Zhang, Zonglei Wang, Cong He, Hongtao Zhu, Nianshuang Li, Junming Li, et al.

    Background and Aims: Helicobacter pylori is a persistent gastric microbe with systemic consequences beyond the stomach, yet its contribution to host lipid dysregulation remains unclear. Methods: We analyzed clinical data from 57,295 adults with documented H. pylori status and detailed lipid profiles, including the non–HDL‐C to HDL‐C ratio (NHHR). Mechanistic validation was performed using in vitro and in vivo H. pylori PMSS1 infection models, combined with single‐cell RNA sequencing, molecular analyses, histopathology, and lipidomics. Results: Helicobacter pylori infection was associated with increased LDL cholesterol and triglycerides, reduced HDL cholesterol, and elevated NHHR, which independently predicted hyperlipidemia risk. At the mechanistic level, H. pylori infection consistently suppressed gastric expression of Gpihbp1, a key mediator of lipoprotein lipase–dependent lipid transport. Infected mice developed systemic hyperlipidemia and exhibited lipidomic remodeling characterized by glycerolipid accumulation and reduced phosphatidylcholine species. Importantly, genetic deficiency of Gpihbp1 promoted gastric H. pylori colonization and exacerbated mucosal inflammation, revealing a reciprocal interaction between host lipid metabolism and bacterial persistence. Conclusion: These findings define a microbiota–host lipid transport axis linking chronic H. pylori infection to dyslipidemia and suggest that integrated targeting of microbial infection and metabolic dysfunction may offer therapeutic benefit.

  • Open Access

    The Pathogenesis and Therapies of Acute Pancreatitis: A Bibliometric Analysis from 2003 to 2025

    by Chenlu Huang, Shujing Xie, Yichen Liu, Yu Li, Guilian Lan, Cong He

    Purpose: Acute pancreatitis (AP) is an inflammatory disorder with rising global incidence. Substantial progress in elucidating AP pathophysiology has been achieved over the past two decades. This study aims to assess the evolution of AP pathogenesis and therapies through quantitative methodologies. Methods: Basic research articles addressing AP pathogenesis and therapies published between 2003 and 2025 were retrieved from the Web of Science database. Bibliometric visualization was performed with VOSviewer and CiteSpace, and statistical graphics with GraphPad Prism. Results: Among 632 publications, China led in output, while the USA had the highest impact. Shanghai Jiao Tong University and Markus M. Lerch were the most productive institution and author, respectively. Pancreas was the leading journal. Keyword analysis revealed key mechanistic themes including “oxidative stress”, “nf-kappa-b”, and “trypsinogen activation”, alongside emerging research foci such as “gut microbiota” and “autophagy”. Rodents were the primary models, with cerulein as the common inducer. Recent hotspots include acinar cell ferroptosis and pyroptosis, alongside pivotal immune themes of neutrophil extracellular traps, macrophage polarization, and Treg/Th17 balance. Innovative therapies encompassed gut microbiota modulation, nanotherapy, and traditional Chinese medicine. Conclusion: This investigation provides methodological references for establishing AP experimental models, and delineates promising future investigative trajectories.


  • Open Access

    Gut microbiota dysbiosis exacerbates acute pancreatitis via Escherichia coli -driven neutrophil heterogeneity and NETosis

    by Yaoyu Zou, Nianshuang Li, Xueyang Li, Maobin Kuang, Xin Xu, Langyi Guan, Xin Li, Pan Zheng, Leyan Li, Jianhua Wan, et al.

    Gut microbiota dysbiosis contributes to acute pancreatitis (AP) severity, but the specific microbes and mechanisms remain unclear. In this study, we employed both germ-free (GF) and specific-pathogen-free (SPF) murine models of AP to investigate the role of the intestinal microbiota. Our findings demonstrate that GF mice exhibited markedly attenuated pancreatic injury, inflammatory cell infiltration, and neutrophil extracellular traps (NETs) formation. Through fecal microbiota transplantation (FMT) from AP patients, differential antibiotic modulation, and single-bacterial colonization experiments, we identified Gram-negative bacteria, particularly Escherichia coli (E. coli), as critical microbial drivers of disease exacerbation. Single-cell RNA sequencing revealed that microbiota dysbiosis profoundly reprogrammed both local pancreatic and systemic immune landscapes. Specifically, dysbiosis promoted emergency granulopoiesis in the bone marrow, enhanced neutrophil mobilization and activation, and facilitated the expansion of pro-inflammatory neutrophil subpopulations (Neutrophils_2 and Neutrophils_3). These subsets exhibited upregulated signaling through NETosis-associated pathways, including TLR, NF-κB, and IL-17 axes. Conversely, in GF conditions, we observed a predominance of an anti-inflammatory neutrophil subset (Neutrophils_4), characterized by the expression of tissue repair-associated genes such as Reg1 and Reg2. Shotgun metagenomic profiling of fecal samples from patients with AP revealed an enrichment of E. coli during the acute phase, positively correlating with circulating cell-free DNA, a marker of NETosis. Together, these insights suggest that gut microbiota dysbiosis, notably increased E. coli abundance, may aggravate AP by reshaping immunity and promoting aberrant NETs formation, supporting microbiota or NETs targeted therapies.


  • Open Access

    Comprehensive characterization of gastrointestinal microbiota dysbiosis in patients with refractory Helicobacter pylori infection

    by Yu Li, Xinbo Xu, Chao Peng, Yichen Liu, Nonghua Lu, Yin Zhu, Cong He

    While repeated Helicobacter pylori eradication attempts are increasingly common due to antimicrobial resistance, the compounding effects of multiple antibiotic courses on gastrointestinal microbiota remain unquantified. We enrolled 32 treatment-naïve patients and 84 patients with refractory H. pylori infections, defined as failure of at least two prior eradication attempts. Antibiotic susceptibility testing was conducted for refractory H. pylori isolates to assess resistance patterns. Gastric mucosal biopsies and fecal samples were obtained for 16S rRNA gene sequencing. Antimicrobial susceptibility testing revealed resistance rates of 96.55% to metronidazole, 77.59% to clarithromycin, 56.90% to levofloxacin, 5.17% to rifampicin, 1.72% to tetracycline, and 0% to amoxicillin and furazolidone. The rates of dual drug and multidrug resistance were 27.59% and 55.17%, respectively. Refractory patients exhibited significant gastric microbiota restructuring, marked by reduced alpha diversity. The refractory group had higher concentrations of pathogens like Pseudomonas and Burkholderia and lower relative abundances of beneficial bacteria, including Bifidobacterium , Blautia , and Roseburia . Levofloxacin-resistant individuals exhibited an amplified abundance of pathogenic Veillonella . The gastric microbial diversity was higher in clarithromycin-resistant patients, with the enrichment of Micromonospora . Compared with the single-resistant group, pathogens, such as Veillonella and Peptostreptococcus , were increased in the multidrug-resistant group. We also observed perturbations of gut microbiota in refractory H. pylori -infected patients, with the predominance of Streptococcus and depletion of Bacteroides . Our findings establish that refractory H. pylori infection induces a disruption of gastrointestinal microbiota, highlighting the importance of optimizing first-line regimens to prevent retreatment cycles and the potential benefit of microbiota-modulating strategies in refractory H. pylori management. IMPORTANCE: Previous research has demonstrated that H. pylori eradication therapies can transiently alter gut microbiota. However, the long-term consequences of repeated antibiotic treatments in refractory infections remain unexplored. In this study, we link failed eradication attempts to persistent gastrointestinal dysbiosis, characterized by increased Pseudomonas and antibiotic-resistant Veillonella , alongside depletion of beneficial bacteria. In addition, we also demonstrate distinct gastric microbiota structure in patients with different antibiotic resistance patterns. Our findings showed distinct microbial dysbiosis after repeated eradication attempts, highlighting the need to explore microbiota-modulating approaches in future clinical trials.


  • Open Access

    Rifaximin reduces gut-derived inflammation in severe acute pancreatitis: an experimental animal model and randomized controlled trial

    by Yao-Yu Zou, Bing-Jun Yu, Cong He, Ling Ding, Xin Xu, Jian-Hua Wan, Yu-Peng Lei, Xin Huang, Hui-Fang Xiong, Wen-Hua He, et al.

    Severe acute pancreatitis (SAP) is characterized by systemic inflammation and intestinal barrier dysfunction and is often associated with gut microbiota dysbiosis. Rifaximin, a gut-specific non-absorbable antibiotic, is known to modulate the gut microbiota. Here, we investigated rifaximin’s effects and mechanisms in SAP using murine models and a single-center, open-label, randomized controlled trial (Chinese Clinical Trial Registry: ChiCTR2100049794). In mice, rifaximin attenuated pancreatic injury and systemic inflammation and altered gut microbiota composition by decreasing mucin-degrading genera such as Akkermansia ( P < 0.05). These protective effects persisted in antibiotic-treated and germ-free mice, suggesting mechanisms not solely dependent on gut microbiota modulation. In patients with predicted SAP ( n = 60), rifaximin significantly reduced systemic inflammation compared with controls. WBC decreased from a median of 11.50 × 10⁹/L (IQR 8.76–15.68) to 8.49 × 10⁹/L (6.93–10.20; P = 0.04) and TNF-α from 15.05 pg/mL (12.73–19.75) to 11.00 pg/mL (8.74–15.40; P = 0.009). However, the incidence of culture-confirmed infection did not differ between the rifaximin and control groups (13.3% vs. 13.3%; RR, 1.00; 95% CI, 0.28–3.63). Adverse events were comparable between groups. Metagenomic analyses revealed suppression of mucin-degrading bacteria (e.g., Akkermansia , Bacteroides fragilis , and Hungatella hathewayi ) ( P < 0.05) and reductions in mucin-degrading carbohydrate-active enzymes, including sialidases and fucosidases. In conclusion, among patients with predicted SAP, rifaximin did not reduce culture-confirmed infectious complications within 90 days after randomization compared with standard care, despite significant improvements in systemic inflammatory markers and selected fecal microbiome features. Larger randomized controlled trials are warranted to validate these findings. IMPORTANCE: Although rifaximin has been used to target gut-derived inflammation in other contexts, its role in SAP remains largely unexplored. In this study, rifaximin treatment was associated with reduced pancreatic injury and systemic inflammation in both murine models and patients with predicted SAP. Treatment also led to changes in gut microbial composition, notably a decrease in mucin-degrading taxa. Importantly, similar protective effects were also observed in antibiotic-treated and germ-free mice, indicating that rifaximin may act via microbiota-dependent and host-directed pathways. These findings offer novel insights into the gut-pancreas axis and suggest that rifaximin holds therapeutic potential by modulating gut microbial composition and host inflammatory responses in SAP.


  • Oral microbes and gastrointestinal cancers: new strategies and insights

    by Chenlu Huang, Yu Li, Cong He

    Gastrointestinal (GI) cancers are among the most prevalent cancers globally and represent a leading cause of cancer-related mortality. A distinctive characteristic of these cancers is their association with the microbes. Gut microbiota dysbiosis is widely recognized as a contributing factor in cancer development. Recent advancements in molecular techniques have increasingly underscored the role of oral microbes in GI cancers, especially colorectal cancer. Oral microbes, transported to the gut via swallowed saliva, have been shown to influence GI health. Both in vivo and in vitro investigations demonstrated the impacts of oral microbes in GI cancers. This review explores the changes in oral microbial diversity and relative abundance in esophageal, gastric and colorectal cancers as well as the underlying mechanisms. These mechanisms include immunomodulation, epigenetics, apoptosis, and others. Among these, immunomodulation stands out due to its close connection with cancer treatment. Finally, we discuss the limitations of the current research and propose new perspectives and directions for future studies.


  • Open Access

    Sex-specific effects of gastrointestinal microbiome disruptions on Helicobacter pylori-induced gastric carcinogenesis in INS-GAS mice

    by Chao Peng, Xin Li, Yu Li, Xinbo Xu, Yaobin Ouyang, Nianshuang Li, Nonghua Lu, Yin Zhu, Cong He

    Background: Accumulating evidence indicates that the dysbiosis of gastrointestinal microbiota is associated with the development of gastric carcinogenesis. However, the sex-specific traits of gastrointestinal microbiota and their correlation with the sexually dimorphic response to gastric cancer remain poorly understood. Methods: Male and female transgenic FVB/N insulin-gastrin (INS-GAS) mice as a model of gastric cancer were randomly administered Brucella Broth or Helicobacter pylori (H. pylori). Stomachs were evaluated by histopathology. The gastric inflammation was examined by immunohistochemical and immunofluorescence staining. Gastric mucosal and fecal samples were collected for microbiota analysis using 16S rRNA gene sequencing. Results: Following H. pylori infection, male mice showed heightened inflammatory infiltration and notably greater intestinal metaplasia compared to female mice. The structure of gastrointestinal microbiota was different between male and female mice, with relative higher diversity in females than males. Notably, we found gender disparities in the alterations of gastric and intestinal microbiota in mice post H. pylori infection. While the enrichment of Bifidobacterium and Lachnospiraceae was observed in female mice, Escherichia_Shigella and Akkermansia were more abundant in males. Furthermore, the microbial profile was distinct in estrogen-deficient ovariectomized (OVX) mice, including the overgrowth of Akkermansia and the loss of Butyricicoccus. Infected OVX females developed significantly more severe gastric lesions, which was normalized through co-housing with intact females. Conclusions: We have identified a novel microbiome-based mechanism that provides insight into the sexual dimorphism in the development of H. pylori-associated gastric cancer.


  • Open Access

    Helicobacter pylori infection induces DNA double-strand breaks through the ACVR1/IRF3/POLD1 signaling axis to drive gastric tumorigenesis

    by Xinbo Xu, Xiao Fei, Huan Wang, Xidong Wu, Yuan Zhan, Xin Li, Yan’aN Zhou, Chunxi Shu, Cong He, Yi Hu, et al.

    Helicobacter pylori (H. pylori) infection plays a pivotal role in gastric carcinogenesis through inflammation-related mechanisms. Activin A receptor type I (ACVR1), known for encoding the type I receptor for bone morphogenetic proteins (BMPs), has been identified as a cancer diver gene across various tumors. However, the specific role of AVCR1 in H. pylori-induced gastric tumorigenesis remains incompletely understood. We conducted a comprehensive analysis of the clinical relevance of ACVR1 by integrating data from public databases and our local collection of human gastric tissues. In vitro cell cultures, patient-derived gastric organoids, and transgenic INS-GAS mouse models were used for Western blot, qRT-PCR, immunofluorescence, immunohistochemistry, luciferase assays, ChIP, and comet assays. Furthermore, to investigate the therapeutic potential, we utilized the ACVR1 inhibitor DM3189 in our in vivo studies. H. pylori infection led to increased expression of ACVR1 in gastric epithelial cells, gastric organoid and gastric mucosa of INS-GAS mice. ACVR1 activation led to DNA double-strand break (DSB) accumulation by inhibiting POLD1, a crucial DNA repair enzyme. The activation of POLD1 was facilitated by the transcription factor IRF3, with identified binding sites. Additionally, treatment with the ACVR1 inhibitor DM3189 significantly ameliorated H. pylori-induced gastric pathology and reduced DNA damage in INS-GAS mice. Immunohistochemistry analysis showed elevated levels of ACVR1 in H. pylori-positive gastritis tissues, showing a negative correlation with POLD1 expression. This study uncovers a novel signaling axis of AVCR1/IRF3/POLD1 in the pathogenesis of H. pylori infection. The upregulation of ACVR1 and the suppression of POLD1 upon H. pylori infection establish a connection between the infection, genomic instability, and the development of gastric carcinogenesis.


  • Open Access

    Exploring the performance of large language models on hepatitis B infection-related questions: A comparative study

    by Yu Li, Chen-Kai Huang, Yi Hu, Xiao-Dong Zhou, Cong He, Jia-Wei Zhong

    BACKGROUND Patients with hepatitis B virus (HBV) infection require chronic and personalized care to improve outcomes. Large language models (LLMs) can potentially provide medical information for patients. AIM To examine the performance of three LLMs, ChatGPT-3.5, ChatGPT-4.0, and Google Gemini, in answering HBV-related questions. METHODS LLMs’ responses to HBV-related questions were independently graded by two medical professionals using a four-point accuracy scale, and disagreements were resolved by a third reviewer. Each question was run three times using three LLMs. Readability was assessed via the Gunning Fog index and Flesch-Kincaid grade level. RESULTS Overall, all three LLM chatbots achieved high average accuracy scores for subjective questions (ChatGPT-3.5: 3.50; ChatGPT-4.0: 3.69; Google Gemini: 3.53, out of a maximum score of 4). With respect to objective questions, ChatGPT-4.0 achieved an 80.8% accuracy rate, compared with 62.9% for ChatGPT-3.5 and 73.1% for Google Gemini. Across the six domains, ChatGPT-4.0 performed better in terms of diagnosis, whereas Google Gemini demonstrated excellent clinical manifestations. Notably, in the readability analysis, the mean Gunning Fog index and Flesch-Kincaid grade level scores of the three LLM chatbots were significantly higher than the standard level eight, far exceeding the reading level of the normal population. CONCLUSION Our results highlight the potential of LLMs, especially ChatGPT-4.0, for delivering responses to HBV-related questions. LLMs may be an adjunctive informational tool for patients and physicians to improve outcomes. Nevertheless, current LLMs should not replace personalized treatment recommendations from physicians in the management of HBV infection.


  • Open Access

    Dietary inulin ameliorates obesity-induced severe acute pancreatitis via gut-pancreas axis

    by Xin Li, Pan Zheng, Yaoyu Zou, Langyi Guan, Nianshuang Li, Jianping Liu, Nonghua Lu, Yin Zhu, Cong He

    Obesity is a definitive factor of severity and mortality of acute pancreatitis (AP), and gut microbiota dysbiosis is involved in its pathogenesis. However, the effect of gut microbiota modulation by dietary components on high fat diet (HFD)-induced severe AP remains unclear. Here, we found that the inulin, a soluble dietary fiber, mitigated pancreatic injury and systematic inflammation in mice fed HFD, which was dependent on gut microbiota as this protective effect was attenuated in germ-free mice. Inulin treatment suppressed the overgrowth of pathogenic bacteria Escherichia Shigella, Enterococcus, Klebsiella, while increased the abundance of probiotics Akkermansia. Fecal microbiota transplantation from inulin-treated mice to recipient mice reduced pancreatic damage and remodeled intestinal homeostasis. Additionally, inulin increased fecal short chain fatty acids (SCFAs), strengthened gut barrier and restored Paneth cells. The beneficial effect of inulin on improving pancreatic damage and leaky gut was diminished after the suppression of SCFAs. Notably, SCFAs administration, especially butyrate, to HFD mice blocked pancreatic and intestinal injury with the inhibition of histone deacetylase 3 (HDAC3), and pharmacological HDAC3 inhibition mimicked the ameliorative effect of SCFAs. Mechanically, butyrate modulated macrophage M1/M2 polarization balance by suppressing HDAC3 and subsequent acetylation of histone H3K27. Collectively, our data offer new insights into the gut microbiota-pancreas axis that may be leveraged to augment the potential supplementation of prebiotic inulin in the management of obesity associated severe AP.